Want to see FR:SIGHT full AI Analyst Report?
Top Page
GenSight Biologics SA
(SIGHT)
Select Model
Select Model
Rating:46Neutral
Price Target:
€0.10
▼(-19.17% Downside)
Action:Reiterated
Date:10/01/26
The score is driven primarily by weak financial performance (revenue collapse, persistent losses, ongoing cash burn, and negative equity), which materially raises funding and solvency risk. Technicals are more neutral than bearish (RSI near 50 and slightly positive MACD), providing limited support. Valuation remains unattractive/unclear due to negative earnings and no dividend yield.
Positive Factors
Debt Reduction
Lower debt is a constructive balance-sheet change that can reduce financing pressure and improve financial flexibility. Although equity remains negative, the reduction may moderate obligations and create a somewhat more manageable capital structure over the next several quarters.
Negative Factors
Revenue Collapse
A near-total revenue collapse demonstrates very limited commercial scale and makes the business highly dependent on future pipeline progress. Persistently weak revenue reduces internally generated funding capacity and increases uncertainty around the timing of a sustainable operating model.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Reduction
Lower debt is a constructive balance-sheet change that can reduce financing pressure and improve financial flexibility. Although equity remains negative, the reduction may moderate obligations and create a somewhat more manageable capital structure over the next several quarters.
Read all positive factors
GenSight Biologics SA (SIGHT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€19.64M
Dividend YieldN/A
Average Volume (3M)1.85M
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth-610.31%
EPS Growth43.88%
CountryFR
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding235,044,330
10 Day Avg. Volume1,812,394
30 Day Avg. Volume1,846,416
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.62
Price to Sales (P/S)15482.52
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.08Price Target Upside-33.33% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.22
Revenue Forecast (FY)€11.20M
GenSight Biologics SA Business Overview & Revenue Model
Company Description
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous s...
GenSight Biologics SA Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -1.26M | 1.00K | 2.63M | 1.27M | 2.58M | 5.28M |
| Gross Profit | -47.00K | 1.00K | 2.63M | 3.00M | 2.58M | 5.28M |
| EBITDA | -13.21M | -11.24M | -14.76M | -21.73M | -26.77M | -25.52M |
| Net Income | -15.34M | -12.04M | -14.00M | -26.22M | -27.62M | -28.62M |
Balance Sheet | ||||||
| Total Assets | 6.46M | 8.26M | 10.76M | 9.13M | 25.94M | 56.65M |
| Cash, Cash Equivalents and Short-Term Investments | 1.67M | 2.42M | 2.46M | 2.13M | 10.61M | 44.29M |
| Total Debt | 12.84M | 12.86M | 19.11M | 23.54M | 12.65M | 12.57M |
| Total Liabilities | 35.76M | 33.20M | 37.68M | 39.83M | 41.22M | 40.66M |
| Stockholders Equity | -33.62M | -24.94M | -26.92M | -30.67M | -15.28M | 15.99M |
Cash Flow | ||||||
| Free Cash Flow | -8.50M | -9.38M | -12.94M | -24.67M | -34.01M | -17.17M |
| Operating Cash Flow | -8.22M | -9.38M | -12.94M | -24.66M | -33.75M | -17.14M |
| Investing Cash Flow | 165.00K | 180.00K | 17.00K | 209.00K | 172.00K | -16.00K |
| Financing Cash Flow | 9.58M | 9.14M | 13.54M | 15.86M | 95.00K | 23.74M |
GenSight Biologics SA Technical Analysis
Negative
0.12
Price Trends
0.10
Negative
0.09
Negative
0.09
Negative
Market Momentum
>-0.01
Positive
32.27
Neutral
5.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:SIGHT, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.10, and above the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.27 is Neutral, neither overbought nor oversold. The STOCH value of 5.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:SIGHT.
GenSight Biologics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €194.80M | -4.19 | -29.36% | ― | 189.81% | 38.50% | |
46 Neutral | €19.64M | -1.15 | 52.39% | ― | -610.31% | 43.88% | |
43 Neutral | €70.57M | -7.34 | -80.82% | ― | -10.38% | -72.05% | |
41 Neutral | €90.70M | -2.16 | -94.14% | ― | -5.98% | -8.67% |
* Healthcare Sector Average
FR:SIGHT
GenSight Biologics SA
0.08
-0.07
-46.10%
FR:ALCOX
Nicox SA
0.32
-0.05
-13.24%
FR:TNG
Transgene
0.70
-0.41
-36.94%
FR:ALCLS
Cellectis SA
1.25
-1.74
-58.13%
FR:ABNX
ABIONYX Pharma SA
1.62
-1.70
-51.19%
GenSight Biologics SA Corporate Events
GenSight Boosts Cash Through Early Access as LUMEVOQ Manufacturing Transfer Completes
Sep 29, 2026
GenSight Biologics reported that while IFRS revenue for the first half of 2026 came in at a negative €1.2 million due to accrued rebates and a non-cash accounting change, the company collected €6.5 million from paid early access progra...
GenSight Biologics Advances GS010 Manufacturing and Early Access Programs Ahead of H1 2026 Results
Sep 8, 2026
GenSight Biologics, a clinical-stage gene therapy company focused on retinal and central nervous system disorders, is advancing a pipeline aimed at restoring vision in patients with rare, blinding diseases. Its lead candidate GS010 for Leber Hered...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.